Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate Effects of Ranibizumab with PDT in CNV Secondary to AMD
NCT00413829Phase 2Completed
- Sponsor
- Insel Gruppe
- Start
- Oct 2006
- Primary completion
- May 2007
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in age-related macular degeneration (AMD), sponsored by Insel Gruppe. Primary endpoint: Incidence of CNV closure at 1 week. Started Oct 2006; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00413829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00413829.